LEZIL-M Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
LEZIL-M
Montelukast 10mg + Levocetirizine Dihydrochloride 5mg
LEZIL-M provides synergistic dual-pathway antiallergic relief by inhibiting histamine-induced peripheral symptoms and blocking cysteinyl leukotriene-mediated airway inflammation.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Selectively antagonizes peripheral H1 histamine receptors while competitively blocking leukotriene D4 receptors in respiratory and dermal pathways.
Usually 1 tablet once daily, preferably administered in the evening or at bedtime.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
LEZIL-M features Montelukast 10mg + Levocetirizine Dihydrochloride 5mg prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Apply for Exclusive Marketing Rights of LEZIL-M
Check vacant territory availability in your state or district. Enjoy full marketing kit support, visual aids, and guaranteed zero competitor supply.
Questions Regarding LEZIL-M
What is the therapeutic indication and composition of LEZIL-M?
LEZIL-M contains Montelukast 10mg + Levocetirizine Dihydrochloride 5mg indicated for Allergic Rhinitis as formulated by Sygnus Biotech.
What packaging presentations are available for LEZIL-M?
LEZIL-M is supplied in tamper-evident 10 x 10 Alu-Alu / Blister Pack, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for LEZIL-M?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for LEZIL-M along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
LEZIL-M is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Tablet
View all Tablet →
DAIBET-G2 V
Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered
